Floatz logo

Bosentan

Pediatric ALL

Duke UniversitySmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Pediatric ALL cohort.

Asset / SponsorPhaseRating
NALBUPHINE
Ain Shams University
Phase 4BB
ROPIVACAINE
Yilin Zhao
Phase 4BB
Beclomethasone
New York City Health and Hospitals Corporation
Phase 4BB
BIVALIRUDIN
University of Texas Southwestern Medical Center
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Ain Shams University
Phase 4BB

View all 40 →

Same molecule, other indications

Bosentan is also rated in:

systemic sclerosisDormant
B
Indicative ·
63 / 100
View asset →
SclerodermaDormant
B
Indicative ·
63 / 100
View asset →
idiopathic pulmonary fibrosisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →